Bank of America Initiates Coverage On Arena Pharmaceuticals with Neutral Rating, Announces $51 Price Target

Bank of America initiates coverage on Arena Pharmaceuticals (NASDAQ:ARNA) with a Neutral rating and a $51 price target.

Benzinga · 11/13/2019 14:28

Bank of America initiates coverage on Arena Pharmaceuticals (NASDAQ:ARNA) with a Neutral rating and a $51 price target.